Research programme: oncolytic virus - Yuhan CorporationAlternative Names: YH-Bio2; YH_Bio2
Latest Information Update: 16 Dec 2014
At a glance
- Originator Yuhan
- Class Oncolytic viruses
- Mechanism of Action Cell death stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Dec 2014 No development reported - Preclinical for Cancer in South Korea (Parenteral)
- 20 Aug 2012 Preclinical trials in Cancer in South Korea (Parenteral)